Sutro Biopharma, Inc.
https://www.sutrobio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sutro Biopharma, Inc.
Genmab And Merck Ramp Up ADC Competition In Ovarian Cancer
Genmab is the latest company to join an escalating arms race in antibody-drug conjugates, challenging AbbVie’s lead in ovarian cancer treatment.
Ipsen Dives Back Into Dealmaking With First ADC Pact
The French drugmaker has teamed up with South San Francisco's Sutro Biophgarma to bag the rights to a preclinical-stage ADC targeting ROR1.
Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE
Plus deals involving Novo Nordisk/Neomorph, Mabwell/Jiangsu Haibo, Alteogen/Merck & Co., Gilead/Biocytogen, AlphaGen/ARTBIO and XOMA/Kinnate.
Finance Watch: $1.3bn In New Venture, Equity Capital Across Three New Funds
Private Company Edition: Revelation Partners amassed $608m, Bioluminescence Ventures emerged with $477m and Abingworth raised $356m for late-stage programs. In recent financings, MapLight closed a $225m series C round while Triveni launched with $92m and Gate garnered $60m in series A rounds.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
- Molecular Diversity
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice